Regeneron Pharmaceuticals Q2 2025 Financial Results

SEC Filing 8-K (0000872589-25-000017)

Regeneron Pharmaceuticals, Inc. reported its financial and operating results for the second quarter of 2025. The company announced a 4% increase in total revenues, reaching $3.68 billion compared to $3.55 billion in the same period last year. Key highlights include a 22% increase in global net sales of Dupixent, reaching $4.34 billion, and a 29% increase in U.S. net sales of EYLEA HD, totaling $393 million. However, total U.S. net sales of EYLEA HD and EYLEA decreased by 25% to $1.15 billion. GAAP EPS increased by 3% to $12.81, while non-GAAP EPS rose by 12% to $12.89. The company also received FDA approvals for Lynozyfic for relapsed or refractory multiple myeloma and Dupixent for bullous pemphigoid and chronic spontaneous urticaria. Additionally, the FDA accepted for priority review the sBLA for Libtayo for adjuvant cutaneous squamous cell carcinoma. Regeneron returned over $2.3 billion to shareholders through share repurchases and dividends and committed over $7 billion to U.S. manufacturing investments and business development.